[1] August, P., & Sibai, B. M. (2024). Preeclampsia: Clinical features and diagnosis. UpToDate.

[2] Duley, L. (2005). Evidence and practice: The magnesium sulphate story. Best Practice & Research. Clinical Obstetrics & Gynaecology, 19(1), 57–74. https://doi.org/10.1016/j.bpobgyn.2004.10.010

[3] Murlidhar, V., & Bolia, S. (2006). Intensive care management of severe pre-eclampsia and eclampsia. Apollo Medicine, 3(1), 102–110. https://doi.org/10.1177/0976001620060115

[4] Bilano, V. L., Ota, E., Ganchimeg, T., Mori, R., & Souza, J. P. (2014). Risk factors of preeclampsia/ eclampsia and its adverse outcomes in low- and middle-income countries: A WHO secondary analysis. PLoS One, 9(3), e91198. https://doi.org/10.1371/journal.pone.0091198

[5] Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M., & Van Look, P. F. (2006). WHO analysis of causes of maternal death: A systematic review. Lancet, 367(9516), 1066–1074. https://doi.org/10.1016/S0140- 6736(06)68397-9

[6] Steegers, E. A., von Dadelszen, P., Duvekot, J. J., & Pijnenborg, R. (2010). Pre-eclampsia. Lancet, 376(9741), 631–644. https://doi.org/10.1016/S0140- 6736(10)60279-6

[7] Sibai, B., Dekker, G., & Kupferminc, M. (2005). Preeclampsia. Lancet, 365(9461), 785–799. https://doi. org/10.1016/S0140-6736(05)17987-2

[8] Rathore, R., Butt, N. F., Iqbal, A., & Khan, M. Z. U. (2010). Complications and outcome of patients of pre-eclampsia and eclampsia presenting to medical wards of Mayo Hospital Lahore. Annals of King Edward Medical University, 16(1), 17.

[9] National Collaborating Centre for Women’s and Children’s Health (UK). (2010). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press.

[10] WHO. (2011). WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia: Summary of recommendations. https://iris.who.int/bitstream/handle/10665/119627/ WHO_RHR_14.17_eng.pdf

[11] Magee, L. A., Miremadi, S., Li, J., Cheng, C., Ensom, M. H., Carleton, B., Côté, A. M., & von Dadelszen, P. (2005). Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. American Journal of Obstetrics and Gynecology, 193(1), 153–163. https://doi.org/10.1016/j.ajog.2004.11.059

[12] Belfort, M. A., Anthony, J., Saade, G. R., Allen, J. C., Jr., & the Nimodipine Study Group. (2003). A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. The New England Journal of Medicine, 348(4), 304–311. https://doi.org/ 10.1056/NEJMoa021180

[13] Euser, A. G., & Cipolla, M. J. (2009). Magnesium sulfate for the treatment of eclampsia: A brief review. Stroke, 40(4), 1169–1175. https://doi.org/10. 1161/STROKEAHA.108.527788

[14] Tukur, J. (2009). The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. Annals of African Medicine, 8(2), 76–80. https://doi.org/10.4103/1596-3519.56232

[15] Zuspan, F. P. (1978). Problems encountered in the treatment of pregnancy-induced hypertension. A point of view. American Journal of Obstetrics and Gynecology, 131(6), 591–597. https://doi.org/10.1016/0002-9378(78)90816-5

[16] Pritchard, J. A., Cunningham, F. G., & Pritchard, S. A. (1984). The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. American Journal of Obstetrics and Gynecology, 148(7), 951–963. https://doi.org/10.1016/ 0002-9378(84)90538-6

[17] Begum, R., Begum, A., Johanson, R., Ali, M. N., & Akhter, S. (2001). A low dose (“Dhaka”) magnesium sulphate regime for eclampsia. Acta Obstetricia et Gynecologica Scandinavica, 80(11), 998–1002. https://doi.org/10.1034/j.1600-0412.2001.801105.x

[18] Uzan, J., Carbonnel, M., Piconne, O., Asmar, R., & Ayoubi, J. M. (2011). Pre-eclampsia: Pathophysiology, diagnosis, and management. Vascular Health and Risk Management, 7(7), 467–474.

[19] Malhan, A., Hyder, M.., Baloch, S., Zahegul, Roshan, S., Dembra, G., & Arshad, M. (2023). Frequency of preeclampsia in pregnant women presenting in a tertiary hospital: Frequency